Treeline is collaborating with Roche to evaluate its BCL6 degrader **TLN-121** in combination with Roche’s CD20xCD3 bispecific antibodies—**glofitamab-gxbm (COLUMVI®)** and **mosunetuzumab-axgb (LUNSUMIO®)**—for treating **B-cell lymphomas**. The partnership includes a clinical trial and supply agreement to assess the potential therapeutic effects of the drug combinations. Both companies aim to advance treatment options for patients with B-cell malignancies through this collaboration.
Standard BioTools files a registration statement for its acquisition of Treeline Biosciences, combining over **$900 million** in expected closing funds with Treeline’s clinical-stage pipeline. The deal includes planned **2027 data updates** for Treeline’s lead programs, **TLN-121** and **TLN-372**, alongside new clinical program launches. The merged entity aims to strengthen its financial and R&D position in biopharmaceutical development.
Treeline Biosciences is accessing a $900 million cash runway through 2029 after completing a reverse merger with Standard BioTools. The funding supports its three Phase 1 oncology programs. The company now lists on a public exchange following the transaction.
